Biotech News
Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies SEATTLE, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage
